Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.


Ugurluer G. , Ozsahin M.

Expert opinion on investigational drugs, vol.23, no.12, pp.1637-54, 2014 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 12
  • Publication Date: 2014
  • Doi Number: 10.1517/13543784.2014.951435
  • Title of Journal : Expert opinion on investigational drugs
  • Page Numbers: pp.1637-54

Abstract

Introduction: Squamous-cell carcinoma of the head and neck (SCCHN) remains a challenging clinical problem, due to the persistent high rate of local and distant failures and the occurrence of secondary primaries. For locally advanced SCCHN, a combination of chemotherapy (CT), radiation or surgery is often used, but there are limitations, which may reduce compliance. Molecular targeted therapies, namely anti-EGFR treatments, are in development with the aim of improving clinical outcomes and mitigating treatment-related toxicities.